S&P 500   0.72 (+6.87%)
DOW   0.72 (+6.87%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.72 (+6.87%)
DOW   0.72 (+6.87%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.72 (+6.87%)
DOW   0.72 (+6.87%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.72 (+6.87%)
DOW   0.72 (+6.87%)
QQQ   271.86 (+2.52%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
Log in

NYSE:TEVATeva Pharmaceutical Industries Stock Price, Forecast & News

$11.64
-0.08 (-0.68 %)
(As of 08/13/2020 04:00 PM ET)
Add
Compare
Today's Range
$11.54
Now: $11.64▼
$11.85
50-Day Range
$11.21
MA: $11.90▼
$12.91
52-Week Range
$6.07
Now: $11.64▼
$13.76
Volume4.86 million shs
Average Volume15.45 million shs
Market Capitalization$12.71 billion
P/E Ratio5.04
Dividend YieldN/A
Beta1.58
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. This segment also develops, manufactures, and sells active pharmaceutical ingredients. The Specialty Medicines segment provides specialty medicines for use in central nervous system and respiratory indications. Its products in the central nervous system area comprise Copaxone for the treatment of relapsing forms of MS; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. This segment's products in the respiratory market include ProAir, ProAir Respiclick, QVAR, Duoresp Spiromax, Qnasl, Braltus, Cinqair/Cinqaero, and Aerivio Spiromax for the treatment of asthma and chronic obstructive pulmonary disease, as well as Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim products in the oncology market. The company has collaboration arrangements with Otsuka Pharmaceutical Co. Ltd. and Regeneron Pharmaceuticals, Inc. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel.
Read More
Teva Pharmaceutical Industries logo

Beat the Market (BTM) Rank™

Analyst Opinion: 1.1Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 3.8 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.68 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNYSE:TEVA
Previous Symbol
CUSIPN/A
CIK818686
Webwww.tevapharm.com
Phone972-3914-8171

Debt

Debt-to-Equity Ratio1.66
Current Ratio1.09
Quick Ratio0.72

Price-To-Earnings

Trailing P/E Ratio5.04
Forward P/E Ratio4.81
P/E Growth0.85

Sales & Book Value

Annual Sales$16.89 billion
Price / Sales0.75
Cash Flow$3.80 per share
Price / Cash Flow3.06
Book Value$13.79 per share
Price / Book0.84

Profitability

EPS (Most Recent Fiscal Year)$2.31
Net Income$-998,000,000.00
Net Margins0.03%
Return on Equity17.88%
Return on Assets4.72%

Miscellaneous

Employees40,039
Outstanding Shares1,092,189,000
Market Cap$12.71 billion
Next Earnings Date11/5/2020 (Estimated)
OptionableOptionable
$11.64
-0.08 (-0.68 %)
(As of 08/13/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TEVA News and Ratings via Email

Sign-up to receive the latest news and ratings for TEVA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Teva Pharmaceutical Industries (NYSE:TEVA) Frequently Asked Questions

How has Teva Pharmaceutical Industries' stock been impacted by COVID-19?

Teva Pharmaceutical Industries' stock was trading at $9.01 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, TEVA shares have increased by 29.2% and is now trading at $11.64.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Teva Pharmaceutical Industries?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teva Pharmaceutical Industries in the last year. There are currently 3 sell ratings, 10 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Teva Pharmaceutical Industries.

When is Teva Pharmaceutical Industries' next earnings date?

Teva Pharmaceutical Industries is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Teva Pharmaceutical Industries.

How were Teva Pharmaceutical Industries' earnings last quarter?

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) issued its quarterly earnings data on Wednesday, August, 5th. The company reported $0.55 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.53 by $0.02. The company earned $3.87 billion during the quarter, compared to analysts' expectations of $3.94 billion. Teva Pharmaceutical Industries had a net margin of 0.03% and a return on equity of 17.88%. Teva Pharmaceutical Industries's revenue for the quarter was down 7.3% on a year-over-year basis. During the same period last year, the business earned $0.60 EPS.
View Teva Pharmaceutical Industries' earnings history.

What guidance has Teva Pharmaceutical Industries issued on next quarter's earnings?

Teva Pharmaceutical Industries issued an update on its FY20 earnings guidance on Wednesday, August, 5th. The company provided EPS guidance of $2.30 to $2.55 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.49. The company issued revenue guidance of $16.6 billion to $17 billion, compared to the consensus revenue estimate of $16.83 billion.

What price target have analysts set for TEVA?

18 brokerages have issued 1 year price targets for Teva Pharmaceutical Industries' shares. Their forecasts range from $8.00 to $16.00. On average, they expect Teva Pharmaceutical Industries' share price to reach $12.36 in the next twelve months. This suggests a possible upside of 6.2% from the stock's current price.
View analysts' price targets for Teva Pharmaceutical Industries.

Has Teva Pharmaceutical Industries been receiving favorable news coverage?

Headlines about TEVA stock have trended extremely negative on Thursday, InfoTrie Sentiment reports. The research group ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Teva Pharmaceutical Industries earned a news sentiment score of -4.1 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the near future.
View the latest news about Teva Pharmaceutical Industries.

Are investors shorting Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries saw a drop in short interest in the month of December. As of December 31st, there was short interest totaling 57,460,000 shares, a drop of 14.7% from the December 15th total of 67,380,000 shares. Based on an average trading volume of 19,350,000 shares, the short-interest ratio is presently 3.0 days.
View Teva Pharmaceutical Industries' Short Interest.

Who are some of Teva Pharmaceutical Industries' key competitors?

Some companies that are related to Teva Pharmaceutical Industries include Takeda Pharmaceutical (TKPYY), ASTELLAS PHARMA/ADR (ALPMY), Royalty Pharma (RPRX), UCB (UCBJF), Genmab A/S (GMAB), Genmab A/S (GNMSF), Alexion Pharmaceuticals (ALXN), Shiseido (SSDOY), BioMarin Pharmaceutical (BMRN), Beigene (BGNE), Merck KGaA (MKGAF), Alnylam Pharmaceuticals (ALNY), Horizon Therapeutics (HZNP), Catalent (CTLT) and Sarepta Therapeutics (SRPT).
View all competitors.

What other stocks do shareholders of Teva Pharmaceutical Industries own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Teva Pharmaceutical Industries investors own include General Electric (GE), NVIDIA (NVDA), AT&T (T), Alibaba Group (BABA), Bank of America (BAC), Gilead Sciences (GILD), Micron Technology (MU), Intel (INTC), Johnson & Johnson (JNJ) and Cisco Systems (CSCO).

Who are Teva Pharmaceutical Industries' key executives?

Teva Pharmaceutical Industries' management team includes the following people:
  • Mr. Kåre Schultz, Pres, CEO & Director (Age 58)
  • Mr. Michael McClellan, Exec. VP & CFO (Age 48)
  • Mr. Mark Sabag, Exec. VP of Global HR (Age 48)
  • Dr. Carlo de Notaristefani, Exec. VP of Global Operations (Age 61)
  • Dr. Hafrun Fridriksdottir, Exec. VP of Global R&D (Age 57)

What is Teva Pharmaceutical Industries' stock symbol?

Teva Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."

Who are Teva Pharmaceutical Industries' major shareholders?

Teva Pharmaceutical Industries' stock is owned by a number of institutional and retail investors. Top institutional investors include Menora Mivtachim Holdings LTD. (1.64%), Phoenix Holdings Ltd. (1.07%), FMR LLC (0.75%), Harel Insurance Investments & Financial Services Ltd. (0.70%), Swiss National Bank (0.40%) and Sumitomo Mitsui Trust Holdings Inc. (0.38%). Company insiders that own Teva Pharmaceutical Industries stock include Brendan P O'grady, David Matthew Stark, Deborah A Griffin, Eric Drape, Hafrun Fridriksdottir, Luzich Partners Llc, Mark Sabag, Michael James Mcclellan, Notaristefani Carlo De, Richard Daniell, Rosemary A Crane, Sol J Barer and Sven Dethlefs.
View institutional ownership trends for Teva Pharmaceutical Industries.

Which institutional investors are selling Teva Pharmaceutical Industries stock?

TEVA stock was sold by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Psagot Investment House Ltd., Alberta Investment Management Corp, State of Wisconsin Investment Board, Personal Resources Investment & Strategic Management Inc., Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management, Cambridge Investment Research Advisors Inc., and Strs Ohio. Company insiders that have sold Teva Pharmaceutical Industries company stock in the last year include Brendan P O'grady, David Matthew Stark, Deborah A Griffin, Eric Drape, Hafrun Fridriksdottir, Luzich Partners Llc, Mark Sabag, Michael James Mcclellan, Richard Daniell, and Rosemary A Crane.
View insider buying and selling activity for Teva Pharmaceutical Industries.

Which institutional investors are buying Teva Pharmaceutical Industries stock?

TEVA stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Menora Mivtachim Holdings LTD., Teacher Retirement System of Texas, Harel Insurance Investments & Financial Services Ltd., Phoenix Holdings Ltd., Bailard Inc., Bank of Montreal Can, and SG Americas Securities LLC.
View insider buying and selling activity for Teva Pharmaceutical Industries.

How do I buy shares of Teva Pharmaceutical Industries?

Shares of TEVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Teva Pharmaceutical Industries' stock price today?

One share of TEVA stock can currently be purchased for approximately $11.64.

How big of a company is Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries has a market capitalization of $12.71 billion and generates $16.89 billion in revenue each year. The company earns $-998,000,000.00 in net income (profit) each year or $2.31 on an earnings per share basis. Teva Pharmaceutical Industries employs 40,039 workers across the globe.

What is Teva Pharmaceutical Industries' official website?

The official website for Teva Pharmaceutical Industries is www.tevapharm.com.

How can I contact Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries' mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. The company can be reached via phone at 972-3914-8171 or via email at [email protected]

This page was last updated on 8/13/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.